CDK4/6 inhibitors promote endogenous retroelement expression and interferon signaling, increase antigen-presentation gene expression, and reduce regulatory T-cell proliferation; pairing CDK4/6 blockade with PRC2 or DNMT-directed agents could align tumor-intrinsic antigen restoration with favorable immune composition (87–89). The gene discussed is CDK4; the disease is neoplasm.